Models of EBV Cancer
- Institution
- Wistar Institute, PA
- Principal investigator
- Samantha Standish Soldan
- Funding
- $302K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
CORE C – PROJECT SUMMARY The Preclinical Models of Epstein-Barr Virus (EBV) Cancer Core provides major resources to the three Program Project Investigators, including viral mutants and strains, EBV+ and EBV- nasopharyngeal carcinoma and gastric carcinoma cell lines; human gastric cancer organoid cultures; patient derived xenografts and other in vivo models of EBV-associated cancers; compound testing; and recombinant viruses. Core C has acquired a large repository of EBV+ and EBV- epithelial (gastric and nasopharyngeal) and lymphoid cell lines that have been fingerprinted and are routinely verified by microsatellite/short terminal repeat (STR) testing to exclude cross- contamination. In collaboration with Dr. Calvin Kuo (Stanford University), gastric cancer organoid cultures that are now continuously available through Core C at The Wistar Institute. Organoids are superior to standard cell culture because they recapitulate many features of the organs that they are derived from, including organ ultrastructure, and mimic the tumor microenvironment. These organoid cultures will provide important tools for studying viral and cellular determinants of Epstein-Barr virus-associated cancers (Project 1) and for drug screening (Projects 2 and 3). Importantly, these organoid cultures are genetically tractable and TP53 and ARID1A knockout organoid cultures are already available in Core C. In addition to cell culture models, Core C routinely performs studies using several murine models of EBV- associated cancers. Patient-derived xenografts that are exclusively maintained in vivo are available for all three Projects. Cell line-derived models of EBV associated gastric carcinoma and NPC have been adapted for bioluminescent imaging studies. These murine models will be used for compound testing (Projects 1-3) in collaboration with Core B. Finally, Core C will provide high-titer, recombinant EBV (Projects 1-3) using a bacterial artificial chromosome system to interrogate the specific contributions of EBV genes to the development of cancer.
LOADING MOONBASE SCORE
Questions for Wistar Institute
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NSF · Wistar InstituteNot yet scored
REU Site: Molecular Basis of Cellular Phenotypes (MBCP)
David Zuzga · $465K · 2026–2029
- NIH · Wistar InstituteNot yet scored
Individualized HIV Curative Combination Strategy against Persistent HIV on ART
Luis J Montaner · $3.6M · 2025–2030
- NIH · Wistar InstituteNot yet scored
MEPCS (Multi-epitope protease cleavage sites) vaccine for protecting against SIV rectal transmission
Qingsheng Li · $658K · 2025–2029